Trials / Completed
CompletedNCT06002893
The Antihypercholestrolemic Effect of a Combined Nutritional Supplementation of Standardized Extracts of Amla, Walnut, Red Yeast Rice and Olive
The Antihypercholestrolemic Pharmacological Effect of a Combined Supplement of Amla Fruit, Walnut Leaves, Red Yeast Rice, and Olive Fruit Extracts Leads to Improvement in Circulatory Levels of LDL-C and Remnant Cholesterol
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 221 (actual)
- Sponsor
- Liaquat University of Medical & Health Sciences · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Nutraceutical lipid-lowering interventions are becoming increasingly popular, particularly among patients who are intolerant or refractory to prescription statins, or who desire alternative non-conventional pharmacological treatment to manage their dyslipidaemia, whether they previously experienced statin intolerance or not. A growing body of preclinical and clinical evidence suggest that the amla (Emblica officinalis) red yeast rice (RYR), olive and walnut leaf extracts posses consideable hpolipidaemic pharmacological effects.
Detailed description
The present exploratory study aimed to assess the safety, efficacy, and patient's satisfaction of a combined supplementation of amla, red yeast rice, olive, and walnut leaf extracts (Cholesfytol NG®) on total cholesterol (TC), low-density lipoprotein - cholesterol (LDL-C), high-density lipoprotein - cholesterol (HDL-C), non-high-density lipoprotein - cholesterol (non-HDL-C), remnant cholesterol (RC) and triglycerides (TG) in hyperlipidaemic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Cholesfytol NG®) supplement | General Practitioner (GP) prescribed oral Cholesfytol NG®) supplement |
Timeline
- Start date
- 2020-03-19
- Primary completion
- 2022-03-31
- Completion
- 2023-07-31
- First posted
- 2023-08-21
- Last updated
- 2023-08-21
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06002893. Inclusion in this directory is not an endorsement.